Intro To Semaglutide / Tirzepatide

In the pursuit of wellness and control over weight-related health issues, Semaglutide (generic for Wegovy®) / Tirzepatide (generic for Mounjaro®) stand out as a new beacon of hope. These medication are the outcome of relentless scientific exploration, reflecting a novel approach to obesity management and metabolic health.

What is Semaglutide / Tirzepatide?

Developed with precision through extensive clinical trials, these medications have made a significant leap in medicinal innovation for weight management treatment. As part of the GLP-1 receptor agonists family, substances that mimic the action of the glucagon-like peptide-1 hormone in the body, this hormone plays a vital role in regulating blood sugar levels and appetite , and proves to be a vital ally in interventions aimed at controlling diabetes and facilitating weight loss.

How Semaglutide / Tirzepatide Work

These medication’s mechanisms are straightforward yet powerful; they tap into the body’s innate hunger regulation system, reducing appetite and caloric intake. Additionally, by decelerating gastric emptying, it extends satiety and curtails the desire to eat, thus tackling the core obstacles faced during weight loss: managing hunger and reducing calorie consumption.

Semaglutide / Tirzepatide’s Impact on Health and Longevity

Beyond weight reduction,  these medications play a strategic role in mitigating risks associated with obesity—like type 2 diabetes, heart conditions, and various forms of  cancer. By aiding in effective weight management, these medications not only help reduce the risk of these conditions but also enhances overall quality of life. Its role in the health and longevity industry is not just as a treatment but as a preventive measure, paving the way for a healthier, more vibrant life.

Side-Effects and Risk Management – Is it Safe?

While their transformative potential is remarkable, these medications necessitate proper medical supervision, patience, and a comprehensive health approach. Embracing these medications come with a responsibility to understand their side effects, which may include nausea, digestive disturbances, and rarely, more serious risks.  Adherence to medical guidance, gradual dose escalation, attentive self-monitoring, and suitable diet and exercise strategies are key to mitigating these risks and ensuring safe and healthy usage.  These medications should not be used for more than 4-6 months, as per individual health requirements. Strict adherence to the advised treatment duration is essential but continuing your success protocol is key in transformative and permanent improvement to you health.

Semaglutide and Tirzepatide Administration: A Simple Weekly Routine

These medications are designed for convenience with a simple subcutaneous injection once weekly. Its user-friendly administration can seamlessly integrate into various lifestyles, providing flexibility and consistency in treatment—a small yet significant weekly action for long-term health benefits.

Want to get started? Click Here!

Semaglutide and Tirzepatide

Giovane Medical buys our Semaglutide and Tirzepatide for our patients from one of the top manufactures in the country BPI Labs

BPI Labs, LLC – a wholly owned subsidiary of Belcher Pharmaceuticals, LLC – is a leading manufacturer of generic injectable medications. Their products are of the highest quality in the industry. And they strive to provide injectable products to help alleviate supply disruption and drug shortages.

Quality is the foundation of BPI Labs. Their strong quality culture is comprised of dedicated, highly skilled & experienced professionals working in strict adherence to the cGMP regulations. Through the use of robotic technologies, their pharmaceutical manufacturing produces the highest quality sterile medications at competitive prices.

The search for effective and safe weight loss treatment seems never-ending. But the newest anti-obesity medications, are still making waves more than a year after their approval by the U.S. Food and Drug Administration in 2021 and 2022, respectively.

The injectable drug, initially only used as diabetes medication, is the first drug since Saxenda (2014) approved to treat chronic weight management in the 70% of American adults who are obese or overweight. Research continues to show the effectiveness of these medications for weight loss.

The bottom line

These medications are FDA-approved injectable medications for chronic weight management. These medications are injected under the skin on your stomach, upper arm, or thigh once a week.

You’ll usually start with a low dose that’s slowly increased until you reach the target dose.

These medications can cause side effects such as nausea, vomiting, and diarrhea, especially within the first several months of treatment.

What are the side effects of these medications?

The side effects are typically mild — especially when compared to the complications associated with overweight and obesity.

People taking Semaglutide or Tirzepatide for weight loss may experience:

● Dizziness

● Fatigue

● Gastrointestinal issues, such as diarrhea, constipation and gassiness

● Headache

● Stomach issues, including nausea, vomiting, pain or distension (bloat) Gastrointestinal issues are the most common complaint among people just starting these medications. But you may be able to reduce the side effects by beginning on a lower dose and then slowly increasing the amount you take.

Avoid Semaglutide or Tirzepatide if you have:

● History of medullary thyroid cancer

● History of gallbladder disease

● History of pancreatitis

● Multiple endocrine neoplasia syndrome type 2 (MEN2)

As Seen In Vanity Fair December 2022

“It should have been no mystery, when the people of Hollywood started dropping dozens of pounds in a matter of weeks, it wasn’t that everyone had suddenly started practicing moderation and logging 10,000 steps. It seemed like overnight everyone knew someone who was injecting Semaglutide, whose brand name is Ozempic. The insulin regulator, developed by the Danish pharmaceutical giant Novo Nordisk in 2012, won FDA approval to treat type 2 diabetes five years later. It works by stimulating insulin release, which helps lower blood sugar levels and slow down food leaving the stomach, in turn making Ozempic users feel satiated for longer periods of time. When doctors noticed that patients using Ozempic were losing weight as a side effect of the drug, Novo Nordisk saw opportunity, conducting clinical trials on obese and overweight individuals to find that its drug did, in fact, lead to weight loss of about 15 percent of body mass in a few weeks or months. Soon the manufacturer started marketing a higher-dose Semaglutide, called Wegovy, to treat obesity. Injections, which, mostly, people give themselves once per week, usually take six to eight weeks to cause significant weight loss.”